HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

CSL sinks to nine-year low on revenue warning, $5B write-down

CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...

By Endpoints News · May 11, 2026 · via Endpoints News
CSL sinks to nine-year low on revenue warning, $5B write-down

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News

Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
May 11, 2026
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
MoneyFiercePharma ↗
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
May 11, 2026
Optimi Health’s IPO Rides Psychedelics Policy Shift
MoneyBriefing
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…
May 11, 2026